Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Update

Immix Biopharma, Inc. (NASDAQ:IMMX) was the recipient of a large decrease in short interest in December. As of December 31st, there was short interest totalling 356,500 shares, a decrease of 11.0% from the December 15th total of 400,500 shares. Based on an average trading volume of 165,700 shares, the short-interest ratio is currently 2.2 days. Currently, 2.2% of the company’s shares are short sold.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Immix Biopharma in a research report on Monday, January 6th.

Institutional Investors Weigh In On Immix Biopharma

A number of hedge funds have recently bought and sold shares of IMMX. Invst LLC acquired a new position in shares of Immix Biopharma during the second quarter worth about $57,000. FNY Investment Advisers LLC purchased a new position in Immix Biopharma in the fourth quarter worth approximately $63,000. Finally, Geode Capital Management LLC grew its holdings in Immix Biopharma by 5.6% during the 3rd quarter. Geode Capital Management LLC now owns 150,082 shares of the company’s stock worth $224,000 after acquiring an additional 7,954 shares in the last quarter. Institutional investors and hedge funds own 11.26% of the company’s stock.

Immix Biopharma Trading Down 1.0 %

IMMX traded down $0.02 during trading hours on Friday, hitting $2.04. 121,030 shares of the company’s stock were exchanged, compared to its average volume of 140,296. The firm has a market cap of $56.12 million, a P/E ratio of -2.40 and a beta of 0.27. Immix Biopharma has a 12-month low of $1.26 and a 12-month high of $5.73. The firm has a 50 day moving average of $2.07 and a 200 day moving average of $1.95.

Immix Biopharma (NASDAQ:IMMX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.08). As a group, research analysts expect that Immix Biopharma will post -0.74 EPS for the current fiscal year.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.